1 February 2023
ODD obtained by Genoscience Pharma from FDA to treat HCC
Genoscience Pharma receives FDA Orphan Drug Designation for ezurpimtrostat to treat HepatoCellular Carcinoma (HCC) Ezurpimtrostat…
Read More
6 January 2023
Genoscience Pharma announces the start of GNS561’s Phase 2b Clinical Trial
Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat (GNS561) to treat hepatocarcinoma…
Read More
27 October 2022
Prix Galien USA 2022: Genoscience Pharma is nominated in the category “Start-up/Biotech”
Genoscience Pharma has been nominated to the Prix Galien USA 2022 A so excited event…
Read More
13 September 2022
Orphan Drug Designation to GNS561 for the treatment of Cholangiocarcinoma to GENFIT
Genoscience Pharma is proud that FDA granted an Orphan Drug Designation to GNS561 (a Genoscience's…
Read More
3 March 2022
Liver Cancer, Phase 1b Clinical results publication
Major First in Class Clinical data! Genoscience is proud to announce a new cornerstone of…
Read More
17 January 2022
GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition
Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed…
Read More
17 December 2021
GENOSCIENCE PHARMA out licenses rights of GNS561 in Europe, US and Canada territories in Cholangiocarcinoma
Genoscience is proud to announce the out-licensing of GNS561 in the cholangiocarcinoma in the United…
Read More
8 November 2021
GNS561, a clinical-stage PPT1 inhibitor is efficient against Hepatocarcinoma via modulation of lysosomal functions
The Genoscience Pharma's team and its collaborators are happy of this new publication in Autophagy…
Read More
13 September 2021
GNS561, active against Cancer Stem Cells.
A new article has been recently published in the #journalofcancer showing that #GNS561, a new #autophagy blocker, offers great…
Read More
Nov. 18, 2020
GNS561’s successful phase 1b trial completed
Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…
Read More
